CST, 45010S, TET2 Antibody

Polyclonal Antibody for studying TET2. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, TET2 Antibody (CST #45010) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity TET2 Antibody recognizes endogenous levels of total TET2 protein. This antibody detects bands of unknown identity at 100, 130, and 160 kDa. Species Reactivity: Human, Mouse, Monkey Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly173 of human TET2 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background Methylation of DNA at cytosine residues is a heritable, epigenetic modification that is critical for proper regulation of gene expression, genomic imprinting, and mammalian development (1,2). 5-methylcytosine is a repressive epigenetic mark established de novo by two enzymes, DNMT3a and DNMT3b, and is maintained by DNMT1 (3, 4). 5-methylcytosine was originally thought to be passively depleted during DNA replication. However, subsequent studies have shown that Ten-Eleven Translocation (TET) proteins TET1, TET2, and TET3 can catalyze the oxidation of methylated cytosine to 5-hydroxymethylcytosine (5-hmC) (5). Additionally, TET proteins can further oxidize 5-hmC to form 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), both of which are excised by thymine-DNA glycosylase (TDG), effectively linking cytosine oxidation to the base excision repair pathway and supporting active cytosine demethylation (6,7). TET2 is the most frequently mutated gene in myeloid dysplastic syndrome (MDS), a dysplasia of myeloid, megakaryocytic, and/or erythroid cell lineages, of which 30% progress to acute myeloid leukemia (AML) (8, 9). It is also mutated in diffuse large B-cell lymphoma (10). TET2 protein expression is often reduced in solid tumors such as prostate cancer, melanoma, and oral squamous cell carcinoma (11-13). Alternate Names FLJ20032; KIAA1546; MDS; Methylcytosine dioxygenase TET2; MGC125715; Probable methylcytosine dioxygenase TET2; tet methylcytosine dioxygenase 2; tet oncogene family member 2; TET2 Specification REACTIVITY: H M Mk SENSITIVITY: Endogenous MW (kDa): 280 SOURCE: Rabbit